Want to see HK:9996 full AI Analyst Report?
Peijia Medical Ltd. (9996) AI Stock Analysis
Top Page
Peijia Medical Ltd.
(HKEX:9996)
The score is held back primarily by weak financial performance driven by persistent losses and negative free cash flow, despite strong gross margins and some revenue scaling. Technicals are moderately supportive with neutral-to-positive momentum and improvement versus mid-term averages, but the stock remains below its 200-day average. Valuation is also constrained because the company is loss-making (negative P/E) and there is no dividend yield data to offset that.
Peijia Medical Ltd. (9996) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 2.55B
- Dividend Yield
- ―
- Average Volume (3M)
- 726.84K
- Price to Earnings (P/E)
- -15.1
- Beta (1Y)
- 1.05
- Revenue Growth
- 21.23%
- EPS Growth
- 36.89%
- Country
- Hong Kong
- Employees
- 1,033
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Peijia Medical Ltd. Business Overview & Revenue Model
Company Description
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (...
Peijia Medical Ltd. Financial Statement Overview
Summary
Financials show solid gross margin (~67% in 2025) and meaningful revenue scale-up, but profitability is not established (negative EBIT and net income; net margin ~-29% in 2025). Liquidity quality is pressured by negative operating cash flow and materially negative free cash flow (about -325M in 2025), despite improvement versus 2023.
Income Statement
38NegativeBalance Sheet
72PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 783.99M | 712.87M | 615.48M | 441.13M | 250.83M | 136.53M |
| Gross Profit | 528.47M | 486.05M | 433.62M | 325.37M | 176.20M | 95.65M |
| EBITDA | -23.96M | -128.29M | -170.64M | -348.52M | -359.90M | -546.54M |
| Net Income | -140.99M | -203.29M | -226.58M | -392.52M | -407.81M | -574.22M |
Balance Sheet | ||||||
| Total Assets | 2.91B | 2.66B | 2.69B | 2.67B | 3.32B | 3.16B |
| Cash, Cash Equivalents and Short-Term Investments | 761.12M | 610.52M | 712.52M | 942.92M | 1.74B | 2.30B |
| Total Debt | 652.57M | 434.22M | 253.40M | 221.13M | 131.88M | 7.63M |
| Total Liabilities | 1.06B | 799.05M | 644.11M | 397.88M | 678.86M | 144.48M |
| Stockholders Equity | 1.84B | 1.85B | 2.03B | 2.27B | 2.64B | 3.02B |
Cash Flow | ||||||
| Free Cash Flow | -81.06M | -325.28M | -285.29M | -899.67M | -506.61M | -506.11M |
| Operating Cash Flow | 18.43M | -20.89M | -5.18M | -583.49M | -376.20M | -436.37M |
| Investing Cash Flow | -190.49M | -317.57M | -140.38M | -386.29M | -463.28M | -424.75M |
| Financing Cash Flow | 325.09M | 212.20M | 10.38M | 85.11M | 117.44M | 741.98M |
Peijia Medical Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9996, the sentiment is Negative. The current price of 3.77 is below the 20-day moving average (MA) of 4.32, below the 50-day MA of 4.74, and below the 200-day MA of 5.29, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 30.58 is Neutral, neither overbought nor oversold. The STOCH value of 17.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9996.
Peijia Medical Ltd. Peers Comparison
Overall Rating
HK:178972Outperform
HK:217267Neutral
HK:130256Neutral- HK:999647.5Neutral
HK:216043Neutral
HK:085341Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1789 | 72Outperform | HKD 5.05B | 11.38 | 13.24% | 2.59% | 16.15% | 31.89% |
| HK:2172 | 67Neutral | HKD 4.71B | 21.31 | 10.38% | 1.74% | 3.83% | -27.04% |
| HK:1302 | 56Neutral | HKD 6.35B | 98.22 | 1.71% | ― | 0.75% | -20.22% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9996 | 48Neutral | HKD 2.55B | -15.11 | -7.65% | ― | 21.23% | 36.89% |
| HK:2160 | 43Neutral | HKD 1.63B | -0.86 | -6.69% | ― | ― | ― |
| HK:0853 | 41Neutral | HKD 11.65B | 31.23 | 6.07% | ― | -3.62% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:9996 | Peijia Medical Ltd. | 3.77 | -2.22 | -37.06% | |
| HK:0853 | MicroPort Scientific Corp | 6.08 | -5.92 | -49.33% | |
| HK:1302 | LifeTech Scientific Corporation | 1.47 | -0.58 | -28.29% | |
| HK:1789 | AK Medical Holdings Ltd. | 4.56 | -1.34 | -22.75% | |
| HK:2160 | MicroPort CardioFlow Medtech Corp. | 1.28 | -4.67 | -78.49% | |
| HK:2172 | MicroPort NeuroTech Limited | 8.05 | -3.93 | -32.77% |
Peijia Medical Ltd. Corporate Events
Peijia Medical Wins NMPA Nod for New Intracranial Drug-Coated Balloon
Peijia Medical has announced that the SeQuent Please CIS paclitaxel drug-coated intracranial balloon dilatation catheter has received registration approval from China’s National Medical Products Administration. The device, developed using B. Br...
Peijia Medical Wins NMPA Nod for GeminiOne Mitral Valve Repair System
Peijia Medical Limited has received approval from China’s National Medical Products Administration for its internally developed GeminiOne Transcatheter Edge-to-Edge Repair System, used in the treatment of mitral regurgitation. The clearance mar...
Peijia Medical Narrows Losses and Extends Lead in China’s TAVR Market
Peijia Medical reported strong interim results for the six months ended June 30, 2026, with revenue rising 20.1% year on year to RMB424.5 million and losses narrowing sharply. EBITDA and profit before tax both turned positive, segment results swung t...
Peijia Medical Sets Board Meeting to Approve Interim Results and Consider Dividend
Peijia Medical Limited has scheduled a board meeting for August 21, 2026 to review and approve the interim results for the six months ended June 30, 2026, and to authorize their publication. The directors will also consider whether to recommend an in...
Peijia Medical posts strong H1 2026 growth on TAVR and neurointerventional expansion
Peijia Medical reported unaudited revenue of about RMB415 million to RMB435 million for the first half of 2026, representing year-on-year growth of roughly 17% to 23%. The company attributed this performance to the continued expansion of its transcat...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026